

## News Release

### **Biofrontera AG Notice of Annual Results 2016**

Leverkusen, Germany, 03 April 2017 - Biofrontera AG (FSE: B8F), the specialist for the treatment of sun-induced skin cancer, will be announcing its financial results for the twelve-month period ended 31 December 2016 on 12 April 2017.

Conference calls for shareholders and interested investors will be held on 12 April 2017 at the following times:

*1.00 pm CEST (7.00am EDT) conference call in German:  
Dial-in number: +49-(0)69 271340800  
Conference code: 77327039#*

*3.00 pm CEST (9.00am EDT) conference call in English:  
Dial-in number Germany: +49-(0)69 271340800  
Dial-in number UK: +44 203 36 45 807  
Dial-in number USA: +1 240 64 50 345  
Dial-in number USA (New York): +1 646 66 37 901  
Conference code: 70646208#*

Ends

Enquiries, please contact:

**Biofrontera AG**

Thomas Schaffer, Chief Financial Officer

+49 (0) 214 87 63 2 0  
[press@biofrontera.com](mailto:press@biofrontera.com)  
[www.biofrontera.com](http://www.biofrontera.com)

**IR Germany: Brainwell Asset Solutions**

Jürgen Benker

+49 (0) 152 08931514

**IR UK: Seton Services**

Toni Vallen

+44(0) 20 7603 6797

**IR/Media US:**

**The Ruth Group**

Lee Roth (Investors)

Kirsten Thomas (Media)

+1 646-536-7012  
[lroth@theruthgroup.com](mailto:lroth@theruthgroup.com)  
+1 508-280-6592  
[kthomas@theruthgroup.com](mailto:kthomas@theruthgroup.com)

## News Release

### About Biofrontera

Biofrontera (FSE: B8F, ISIN DE0006046113) is a biopharmaceutical company specializing in the development, sale and distribution of drugs, medical devices and medical cosmetics for the care and treatment of skin diseases. Biofrontera's lead product is Ameluz<sup>®</sup>, a topical prescription drug which is approved and marketed in Europe and the U.S. in combination with its medical lamp BF-RhodoLED<sup>®</sup> for photodynamic therapy (PDT) treatment of mild and moderate actinic keratosis. Ameluz<sup>®</sup> is also approved in the EU for the treatment of superficial and nodular basal cell carcinomas. Biofrontera is the first German pharmaceutical start-up company to obtain centralized EU and now U.S. approval for a medical device/drug it has developed itself.

The company also markets the Belixos<sup>®</sup> dermatological range of cosmetics. Belixos<sup>®</sup> products contain combinations of active substances extracted from plants, and are used for the regenerative care of chronic skin conditions such as atopic dermatitis or psoriasis. Belixos<sup>®</sup> Protect, a daily skincare for sun-damaged skin, complements this dermo-cosmetic line. All Belixos<sup>®</sup> products are available in Europe through Amazon.

The Biofrontera Group was established in 1997 by Prof. Dr. Hermann Lübbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany. For more information, visit <http://www.biofrontera.com>

*This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.*